Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease.

Aged Brain / diagnostic imaging Cerebral Cortex / diagnostic imaging Corpus Striatum / diagnostic imaging Deep Brain Stimulation Female Glucose / metabolism Humans Male Middle Aged Parkinson Disease / diagnostic imaging Positron-Emission Tomography Subthalamic Nucleus Treatment Outcome Vesicular Monoamine Transport Proteins / metabolism
Deep brain stimulation Dopamine Glucose metabolism Parkinson's disease Positron emission tomography (PET) Sub-thalamic nucleus VMAT2

Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
07 2019
Historique:
received: 18 12 2018
revised: 04 04 2019
accepted: 07 04 2019
pubmed: 6 5 2019
medline: 22 5 2020
entrez: 5 5 2019
Statut: ppublish

Résumé

Deep brain stimulation (DBS) is an established treatment for Parkinson's Disease (PD). Despite the improvement of motor symptoms in most patients by sub-thalamic nucleus (STN) DBS and its widespread use, the neurobiological mechanisms are not completely understood. The objective of the present study was to elucidate the effects of subthalamic nucleus (STN) DBS in PD on the dopamine system and neural circuitry, employing high-resolution positron emission tomography (PET) imaging. The hypotheses tested were that STN DBS would decrease the striatal vesicular monoamine transporter (VMAT2), secondary to an increase in dopamine concentrations, and would decrease striatal cerebral metabolism and increase cortical cerebral metabolism. PET imaging of the vesicular monoamine transporter (VMAT2) and cerebral glucose metabolism was performed prior to DBS surgery and after 4-6 months of STN stimulation in seven PD patients (mean age 67 ± 7). The patients demonstrated significant improvement in motor and neuropsychiatric symptoms after STN DBS. Decreased VMAT2 was observed in the caudate, putamen and associative striatum and in extra-striatal, cortical and limbic regions. Cerebral glucose metabolism was decreased in striatal sub-regions and increased in temporal and parietal cortices and the cerebellum. Decreased striatal VMAT2 was correlated with decreased striatal and increased cortical and limbic metabolism. Improvement of depressive symptoms was correlated with decreased VMAT2 in striatal and extra-striatal regions and with striatal decreases and cortical increases in metabolism. The present results support further investigation of the role of VMAT2, and associated changes in neural circuitry in the improvement of motor and non-motor symptoms with STN DBS in PD.

Identifiants

DOI: 10.1016/j.parkreldis.2019.04.006 PMID: 31053531 PMC: PMC7304230
pubmed: 31053531
pii: S1353-8020(19)30201-9
doi: 10.1016/j.parkreldis.2019.04.006
pmc: PMC7304230
mid: NIHMS1528308
pii:
doi:

Substances chimiques

SLC18A2 protein, human 0
Vesicular Monoamine Transport Proteins 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

235-241

Subventions

Organisme : NIA NIH HHS
ID : K23 AG044441
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS101096
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001077
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001079
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Lancet Neurol. 2006 Jun;5(6):525-35
pubmed: 16713924
Neurobiol Dis. 2019 Apr;124:176-182
pubmed: 30471418
Eur Neurol. 2003;50(2):94-9
pubmed: 12944714
J Int Neuropsychol Soc. 2004 Mar;10(2):301-3
pubmed: 15012851
Mov Disord. 2003 Jan;18(1):41-8
pubmed: 12518299
Nat Clin Pract Neurol. 2006 Jun;2(6):310-20
pubmed: 16932575
Neurosurgery. 2003 Nov;53(5):1095-102; discussion 1102-5
pubmed: 14580276
Synapse. 1997 Jan;25(1):1-14
pubmed: 8987142
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
Synapse. 2003 Jul;49(1):20-8
pubmed: 12710012
Parkinsons Dis. 2011 Mar 06;2011:572743
pubmed: 21437185
Ann Neurol. 1996 Dec;40(6):873-84
pubmed: 9007092
J Cereb Blood Flow Metab. 2004 Jan;24(1):7-16
pubmed: 14688612
J Neurol. 2009 Jan;256(1):83-8
pubmed: 19221846
N Engl J Med. 1967 Feb 16;276(7):374-9
pubmed: 5334614
J Consult Clin Psychol. 1988 Feb;56(1):123-30
pubmed: 3346437
Lancet Neurol. 2006 Jul;5(7):578-88
pubmed: 16781988
J Neurol. 2008 Aug;255(8):1236-43
pubmed: 18563467
Lancet Neurol. 2012 May;11(5):429-42
pubmed: 22516078
Brain. 2006 Oct;129(Pt 10):2667-78
pubmed: 16844713
Adv Neurol. 2001;86:237-47
pubmed: 11553983
Biol Psychiatry. 2014 Apr 15;75(8):647-52
pubmed: 23938318
Lancet. 1976 Feb 7;1(7954):292-6
pubmed: 55599
Neuroimage. 2007 Jan 15;34(2):661-70
pubmed: 17113789
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Brain. 2011 Nov;134(Pt 11):3290-8
pubmed: 22075521
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Synapse. 2009 Aug;63(8):713-6
pubmed: 19391152
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Am J Psychiatry. 1997 Apr;154(4):490-6
pubmed: 9090335
Synapse. 2010 Jun;64(6):417-20
pubmed: 20169578
Ann Neurol. 2016 Mar;79(3):448-63
pubmed: 26696272
Am J Psychiatry. 2002 May;159(5):746-54
pubmed: 11986127
Mov Disord. 1999 Jul;14(4):572-84
pubmed: 10435493

Auteurs

Gwenn S Smith (GS)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: gsmith95@jhmi.edu.

Kelly A Mills (KA)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Greg M Pontone (GM)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

W Stanley Anderson (WS)

Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Kate M Perepezko (KM)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

James Brasic (J)

Section of High Resolution Brain PET, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Yun Zhou (Y)

Section of High Resolution Brain PET, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Jason Brandt (J)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Christopher R Butson (CR)

Scientific Computing & Imaging (SCI) Institute, Departments of Biomedical Engineering, Neurology, Neurosurgery & Psychiatry, University of Utah, USA.

Daniel P Holt (DP)

Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

William B Mathews (WB)

Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Robert F Dannals (RF)

Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Dean F Wong (DF)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Section of High Resolution Brain PET, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Zoltan Mari (Z)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Noyaux gris centraux › Corps strié › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Procédures de chirurgie opératoire › Stimulation cérébrale profonde › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Glucides › Sucres › Oses › Hexose › Glucose › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Maladie de Parkinson › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Diencéphale › Subthalamus › Noyau subthalamique › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Effect of STN DBS on vesicular monoamine...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Transporteurs de neurotransmetteurs › Transporteurs vésiculaires des neurotransmetteurs › Transporteurs vésiculaires des amines biogènes › Transporteurs vésiculaires des monoamines › Effect of STN DBS on vesicular monoamine...